<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144274</url>
  </required_header>
  <id_info>
    <org_study_id>18.487</org_study_id>
    <nct_id>NCT00144274</nct_id>
  </id_info>
  <brief_title>Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis</brief_title>
  <official_title>Efficacy and Tolerability of Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis - A Randomised, Double-blind, Placebo-controlled Parallel Group Study. AMBROSIA: Ambroxol Lozenges In Sore Throat In Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate efficacy and tolerability of lozenges containing&#xD;
      20mg am broxol hydrochloride relative to placebo in relieving pain of sore throat in&#xD;
      adolescent patients suf fering from acute viral pharyngitis. The primary endpoint is the&#xD;
      time-weighted average of the pain intensity difference from pre-dose bas eline over the first&#xD;
      3 hours after the first lozenge expressed as a ratio of the pre-dose baseline ( SPIDnorm).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to investigate efficacy and tolerability of lozenges containing&#xD;
      20mg am broxol hydrochloride relative to placebo in relieving pain of sore throat in&#xD;
      adolescent patients suf fering from acute viral pharyngitis. The pain intensity will be&#xD;
      assessed by the patient on a 6-point rating scale before taking the first lozenge and 30, 60,&#xD;
      120 and 180 minutes thereafter. The patient enters the rating in the patient's diary.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      It will be tested whether a statistically significant difference exists in the S PIDnorm&#xD;
      after the intake of the 1st lozenge between the group treated with ambro xol lozenges and the&#xD;
      group treated with placebo lozenges.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      Placebo comparison&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the time-weighted average of the pain intensity difference from pre-dose baseline over the first 3 hours after the first lozenge expressed as a ratio of the pre-dose baseline (SPIDnorm).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity (PI) and pain intensity difference from pre-dose baseline Time to onset of action of lozenge Assessment of redness of pharyngeal mucosa at pre-dose baseline and end of study Efficacy and tolerability assessment Adverse events</measure>
  </secondary_outcome>
  <enrollment>220</enrollment>
  <condition>Pharyngitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol Lozenge</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Patients having a sore throat with acute viral pharyngitis.&#xD;
&#xD;
          2. Female and male patients from 12 and less than 18 years of age.&#xD;
&#xD;
          3. The throat pain intensity is rated at least &quot;moderate&quot; on the VRS(PI).&#xD;
&#xD;
          4. Written Informed Consent is given by the patient's parent/legal guardian, an d the&#xD;
             patient is able to give Assent.&#xD;
&#xD;
          5. Compliance by the patient seems guaranteed, and the patient seems to be able to&#xD;
             understand and complete the patient diary.&#xD;
&#xD;
          6. Patient able to remain at the doctor's practice for the initial 3 hours follo wing the&#xD;
             first intake of study medication, or known reliable patient, and able t o return for&#xD;
             the study visits.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Female patients who have begun menstruating and are:&#xD;
&#xD;
               1. Pregnant&#xD;
&#xD;
               2. Currently breastfeeding&#xD;
&#xD;
               3. Of child-bearing potential and are NOT practicing acceptable methods of birth&#xD;
                  control, or do NOT plan to continue practicing an acceptable method throughout&#xD;
                  the study. Acceptable methods of birth control include surgical sterilisation,&#xD;
                  intra uterine device, oral, implantable or injectable contraceptives. Abstinenc e&#xD;
                  can be used as contraception, at the discretion of the investigator.&#xD;
&#xD;
          2. Patients with symptoms of primarily bacterial pharyngitis or bacterial secon dary&#xD;
             infection (clinical findings inter alia assessment of exudate).&#xD;
&#xD;
          3. First indication of symptoms of acute pharyngitis (e.g. sore throat) occurre d more&#xD;
             than 3 days ago.&#xD;
&#xD;
          4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.&#xD;
&#xD;
          5. Patient who in the past week, or during the study will require treatment with the&#xD;
             following: antibiotics analgesics anti-inflammatory agents steroids fo r oral,&#xD;
             inhaling or topical application expectorants or antitussives. No phys ical therapy&#xD;
             (e.g. throat compress) may be applied during the trial.&#xD;
&#xD;
          6. Patients with mouth breathing as a result of nasal congestion.&#xD;
&#xD;
          7. Known hypersensitivity to Ambroxol or to auxiliary substances contained in t he&#xD;
             lozenge.&#xD;
&#xD;
          8. Previous and/or existing tumour condition.&#xD;
&#xD;
          9. Alcohol, and/or drug abuse.&#xD;
&#xD;
         10. Any clinical condition which, in the opinion of the investigator would not a llow safe&#xD;
             completion of the protocol and safe administration of trial medication.&#xD;
&#xD;
         11. Any investigational therapy within 30 days prior to randomisation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. South Africa (Pty.) Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <zip>1461</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7945</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2033</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2192</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midrand</city>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0038</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandton</city>
        <zip>2021</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/18/18.487_U06-1404.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

